| Multiple Myeloma

Darzalex Faspro vs Pomalyst

Side-by-side clinical, coverage, and cost comparison for multiple myeloma.

Deep comparison between: Darzalex Faspro vs Pomalyst with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsPomalyst has a higher rate of injection site reactions vs Darzalex Faspro based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Pomalyst but not Darzalex Faspro, including UnitedHealthcare

Category

Darzalex Faspro

Pomalyst

At A Glance

RouteSC injection

FrequencyWeekly, then every 2 weeks, then every 4 weeks

ClassCD38-directed monoclonal antibody

RouteOral

FrequencyOnce daily, Days 1-21 of 28-day cycles

ClassThalidomide analogue (immunomodulatory)

Indications

Multiple Myeloma
Smoldering myeloma
Light chain (AL) amyloidosis

Multiple Myeloma
Kaposi Sarcoma

Dosing

Multiple Myeloma 1,800 mg daratumumab and 30,000 units hyaluronidase SC into abdomen over 3-5 minutes. Weekly for 8 weeks, then every 2 weeks for 16 weeks, then every 4 weeks until disease progression. Dosing schedule varies by combination regimen (with lenalidomide-dexamethasone, bortezomib-melphalan-prednisone, bortezomib-thalidomide-dexamethasone, bortezomib-lenalidomide-dexamethasone, bortezomib-dexamethasone, pomalidomide-dexamethasone, or carfilzomib-dexamethasone) or as monotherapy.

Smoldering myeloma 1,800 mg daratumumab and 30,000 units hyaluronidase SC into abdomen over 3-5 minutes. Weekly for 8 weeks, then every 2 weeks for 16 weeks, then every 4 weeks until diagnosis of multiple myeloma or maximum 3 years.

Light chain (AL) amyloidosis 1,800 mg daratumumab and 30,000 units hyaluronidase SC into abdomen over 3-5 minutes in combination with bortezomib-cyclophosphamide-dexamethasone. Weekly for 8 weeks, then every 2 weeks for 16 weeks, then every 4 weeks until disease progression or maximum 2 years.

Multiple Myeloma 4 mg once daily orally with or without food on Days 1 through 21 of each 28-day cycle until disease progression; given in combination with dexamethasone.

Kaposi Sarcoma 5 mg once daily orally with or without food on Days 1 through 21 of each 28-day cycle until disease progression or unacceptable toxicity; continue HAART as HIV treatment in patients with AIDS-related KS.

Contraindications

Severe hypersensitivity to daratumumab, hyaluronidase, or any component of the formulation

Pregnancy
Severe hypersensitivity (e.g., angioedema, anaphylaxis) to pomalidomide or any excipient

Drug Interactions

288View drug interactions

1413View drug interactions

Adverse Reactions

Most common (>=20%) Upper respiratory tract infection, fatigue, peripheral neuropathy, musculoskeletal pain, constipation, diarrhea, insomnia, rash, edema, pyrexia, nausea, cough, dyspnea, sensory neuropathy, injection site reactions, infusion reactions, headache, decreased appetite, sleep disorder

Serious Pneumonia, cardiac failure, sepsis, thromboembolism, COVID-19, neutropenia, thrombocytopenia, arrhythmia, cardiac arrest, herpes zoster, hepatitis B reactivation, cytomegalovirus infection, listeriosis, atrial fibrillation, pancreatitis, pulmonary edema, anaphylactic reaction

Most common (>=10%) Neutropenia, anemia, fatigue/asthenia, constipation, nausea, diarrhea, dyspnea, upper respiratory tract infection, pneumonia, back pain, peripheral neuropathy, edema peripheral, pyrexia, thrombocytopenia, rash

Serious Venous and arterial thromboembolism, hematologic toxicity (neutropenia, thrombocytopenia, febrile neutropenia), hepatotoxicity, severe cutaneous reactions, pneumonia, sepsis, dizziness and confusional state, neuropathy, tumor lysis syndrome

Postmarketing Pancytopenia, hepatic failure, Stevens-Johnson Syndrome, toxic epidermal necrolysis, DRESS, progressive multifocal leukoencephalopathy, hepatitis B virus reactivation, herpes zoster, tumor lysis syndrome, basal cell carcinoma, squamous cell carcinoma of the skin

Pharmacology

Daratumumab is a CD38-directed IgG1 kappa monoclonal antibody that induces tumor cell death through multiple immune-mediated mechanisms including complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, antibody-dependent cellular phagocytosis, and direct apoptosis via Fc-mediated crosslinking.

Pomalidomide is a thalidomide analogue with immunomodulatory, antiangiogenic, and antineoplastic properties; it acts through cereblon (a cullin ring E3 ubiquitin ligase component), targeting substrate proteins Aiolos and Ikaros for ubiquitination and degradation, producing direct cytotoxic and immunomodulatory effects including enhanced T cell- and NK cell-mediated immunity and inhibition of pro-inflammatory cytokines (TNF-alpha and IL-6).

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Darzalex Faspro